Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Arena Pharmaceuticals
San Diego, California, United Statesarenapharm.com ↗
- Ownership
- Private
- Employees
- ~350
- Development stage
- Other
01
Overview
Arena’s leading asset, etrasimod, a selective oral S1P receptor modulator, showed promising Phase 2 results in ulcerative colitis; results from the Phase 3 ELEVATE-UC trial were anticipated in 2022. The company’s other assets were in Phase 2/early Phase 3 with differentiated mechanisms for immuno-inflammatory and cardiovascular indications.
- Therapeutic areas
- CardiovascularGastroenterologyDermatologyRheumatology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Partnerships
Boehringer Ingelheim (GPCR research partnership)Eisai (prior marketing partner for Belviq/lorcaserin for obesity)
Beyond the preview
Go deeper on Arena Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arena Pharmaceuticals.